Vanda Pharmaceuticals Inc. has recently updated its ownership structure, as detailed in a filing made on November 13, 2026. The filing reveals that AQR Capital Management, along with its subsidiary, now holds a significant 3.47% stake in the company. This update is notable as it indicates growing investment interest in Vanda, which is engaged in the pharmaceutical preparations industry.

Background

Vanda Pharmaceuticals Inc. is a company focused on developing and commercializing innovative therapies to address unmet medical needs. It operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. The company is publicly traded under the ticker VNDA on the Nasdaq exchange. Recent filings include a Schedule 13G/A on November 13, 2026, and a Schedule 13G on November 10, 2026, among others.

What the Filing Says

The recent Schedule 13G/A filing indicates that AQR Capital Management, LLC and AQR Capital Management Holdings, LLC collectively own 2,096,939 shares of Vanda Pharmaceuticals, which amounts to 3.47% of the company's common stock. The filing states, "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business." This suggests that the investment was made without intentions of influencing control over the company.

Impact

This increase in stake by AQR Capital Management could have several implications for Vanda Pharmaceuticals. With a notable shareholding, AQR may have a voice in corporate governance matters, potentially influencing strategic decisions. The investment also signals confidence in Vanda's business model and future prospects, which could attract further interest from other institutional investors.

What's Next

The filing does not say what happens next.